CollPlant Biotechnologies (NASDAQ:CLGN) Earns “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a report issued on Wednesday,Benzinga reports. They currently have a $14.00 price target on the stock.

Several other equities research analysts have also recently weighed in on the company. EF Hutton Acquisition Co. I raised CollPlant Biotechnologies to a “strong-buy” rating in a research note on Monday, August 5th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a research report on Wednesday, August 21st.

CollPlant Biotechnologies Stock Performance

CollPlant Biotechnologies stock opened at $4.48 on Wednesday. CollPlant Biotechnologies has a fifty-two week low of $3.31 and a fifty-two week high of $6.99. The stock has a market cap of $51.30 million, a price-to-earnings ratio of -2.91 and a beta of 0.44. The stock’s 50 day simple moving average is $4.29 and its two-hundred day simple moving average is $4.83.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLGN. Benjamin Edwards Inc. bought a new stake in CollPlant Biotechnologies in the third quarter worth $112,000. Villere ST Denis J & Co. LLC raised its position in shares of CollPlant Biotechnologies by 24.4% in the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after purchasing an additional 95,000 shares during the last quarter. Finally, Pinnacle Associates Ltd. boosted its stake in CollPlant Biotechnologies by 6.4% in the 2nd quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock worth $2,805,000 after purchasing an additional 33,905 shares in the last quarter. Institutional investors own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.